Sweet's syndrome in a severely neutropenic patient during therapy with recombinant human granulocyte colony-stimulating factor.
We report a new case of Sweet's syndrome (SS) associated with recombinant human granulocyte colony-stimulating factor (rHuG-CSF) therapy in a patient with acute myelogenous leukemia (AML). The patient developed a fever in association with multiple tender, purpuric and pustular skin lesions and swelling of both calves after receiving rHuG-CSF 3 micrograms/kg/d for 4 days. The absolute neutrophil count was 0.55 x 10(9)/L at onset. A skin biopsy revealed a dense neutrophilic infiltration in the dermis without evidence of vasculitis or infection. All skin and calf lesions regressed within 1 week after prednisolone therapy. Physicians should be aware of potential neutrophil-mediated dermatoses in patients with severe neutropenia on rHuG-CSF treatment.
Chao
S C
SC
Department of Dermatology, National Cheng-Kung University, Tainan.
Lee
J Y
JY
Tsao
C J
CJ
D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications* / Q000175:diagnosis; D011994:Recombinant Proteins; D016463:Sweet Syndrome / Q000150:complications / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor